In a pre‑hospital patient with a moderate‑to‑severe asthma exacerbation who cannot tolerate inhaled bronchodilators (puffers) and is not in imminent cardiac or respiratory arrest, should intravenous magnesium sulfate be given, and what is the appropriate adult dose and monitoring?

Intravenous Magnesium Sulfate for Pre-Hospital Moderate-to-Severe Asthma

In a pre-hospital patient with moderate-to-severe asthma who cannot tolerate inhaled bronchodilators and is not near death, intravenous magnesium sulfate should be administered at 2 g over 20 minutes as a single dose, but only after at least one hour of intensive conventional therapy has failed. 1

Critical Pre-Administration Requirements

Do not administer magnesium sulfate in the pre-hospital setting unless:

• The patient has already received at least 1 hour of intensive conventional therapy (continuous β-agonists and systemic corticosteroids) with inadequate response 1
• The exacerbation is truly severe and refractory—magnesium provides no benefit in mild-to-moderate asthma and should not be used in these cases 1, 2
• The patient shows signs of severe refractory asthma despite initial treatment 1

Common pitfall: Administering magnesium too early in the treatment algorithm reduces its effectiveness and wastes resources. 1 The evidence consistently shows benefit only in patients who have failed first-line therapy for at least one hour. 1, 3

Dosing Protocol

Adult dose: 2 g magnesium sulfate intravenously infused over 20 minutes as a single administration 1, 4

• Dilute the 50% solution to a concentration of 20% or less prior to IV infusion 4
• The rate of IV injection should generally not exceed 150 mg/minute 4
• Administer in 250 mL of 5% dextrose or 0.9% sodium chloride 4

Do not repeat the dose. If clinical improvement is absent after the single infusion, additional magnesium should not be administered. 1

Monitoring During Administration

Essential monitoring parameters include: 4

• Patellar reflex (knee jerk) before and during administration—if absent, hold magnesium 4
• Respiratory rate (maintain ≥16 breaths/minute) 4
• Blood pressure (watch for hypotension) 1, 4
• Clinical response to treatment 4

Target therapeutic serum magnesium level: 3 to 6 mg/100 mL (2.5 to 5 mEq/L) 4

• Deep tendon reflexes begin to diminish when magnesium exceeds 4 mEq/L 4
• Reflexes may be absent at 10 mEq/L, where respiratory paralysis becomes a potential hazard 4

Expected Clinical Benefits

If the patient responds appropriately, expect: 1, 2

• Reduced odds of hospital admission (OR 0.75, translating to 7 fewer admissions per 100 patients treated) 2
• Significant increases in FEV₁, peak expiratory flow, and forced vital capacity within 50–110 minutes 1
• Higher emergency department discharge rates compared to placebo 1

The evidence is strongest for severe exacerbations. A landmark 1995 study showed that in severe asthma (baseline FEV₁ <25% predicted), magnesium reduced admission rates from 78.6% to 33.3% (p=0.009), while showing no benefit in moderate cases. 3

Management of Non-Responders

If the patient fails to improve after the single magnesium dose: 1

• Do not repeat magnesium—there is no evidence supporting multiple doses 1
• Escalate care immediately if any of the following develop: 1
  • Deteriorating peak flow despite treatment
  • Worsening hypoxia despite 60% oxygen
  • Hypercapnia (PaCO₂ >6 kPa or >45 mmHg)
  • Exhaustion or altered mental status
  • Inability to speak
  • Intercostal retractions
  • PaCO₂ ≥42 mmHg
• Consider heliox-driven albuterol nebulization as an alternative bronchodilator strategy 1
• Prepare for intubation if signs of impending respiratory failure develop 1

Safety Profile and Adverse Effects

Common adverse effects (generally mild and self-limited): 1, 4

• Flushing and sweating 1, 4
• Light-headedness and fatigue 1
• Nausea and headache 1
• Transient hypotension 1, 4

Have calcium gluconate immediately available to counteract potential magnesium toxicity 4

Evidence Quality and Nuances

The 2014 Cochrane review of 14 studies (2,313 patients) provides high-quality evidence that IV magnesium reduces hospital admissions (OR 0.75) and improves lung function in adults with acute asthma who have not responded to oxygen, nebulized β-agonists, and IV corticosteroids. 2 However, a 2023 meta-analysis found that only two out of three studies showed benefit when assessed by FEV₁/PEF, and fewer were positive for hospital admission outcomes. 5

Critical distinction: One negative 2001 study found magnesium ineffective, but this trial administered magnesium earlier in the treatment course without the required 1-hour conventional therapy period. 6 This underscores the importance of timing—magnesium works only in truly refractory cases. 1, 3

Route comparison: A 2014 review comparing nebulized versus IV magnesium concluded that in adults, IV administration is the most effective route, though both are well-tolerated and inexpensive. 7

Contraindications and Special Populations

Absolute contraindications: 1

• Mild-to-moderate asthma exacerbations—magnesium provides no measurable benefit and should not be used 1

Use with extreme caution in: 4

• Patients with renal impairment (maximum 20 g/48 hours with frequent serum magnesium monitoring) 4
• Digitalized patients (serious cardiac conduction changes and heart block may occur) 4
• Patients receiving neuromuscular blocking agents (excessive neuromuscular block can occur) 4